C4 Therapeutics (CCCC) PT Lowered to $22 at UBS

February 24, 2023 7:18 AM

UBS analyst Colin Bristow lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $22.00 (from $24.00) while maintaining a Buy rating.

No results found